Diroximel fumarate is an oral medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is designed to reduce the number of MS relapses and slow the progression of disability. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Vumerity and Fumarate de diroximel. Its PubChem CID is 73330464.
Diroximel fumarate
| CAS No | 1577222-14-0 |
|---|---|
| Molecular Formula | C11H13NO6 |
| Molecular Weight | 255.22 g/mol |
| Synonyms | 4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Diroximel fumarate is an oral medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The listed CAS number is 1577222-14-0.
The listed molecular formula is C11H13NO6.
The listed molecular weight is 255.22 g/mol.
4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate.
The source lists Vumerity and Fumarate de diroximel.